Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar

Completed

• Conditions: Day-3 Positive of Parasitaemia; Prevalence of Drug Resistance Gene Mutation

• Registration Number: NCT02198573
• Lead Sponsor: Myat Htut Nyunt

Brief Summary

* Artemisinin resistance have been documented in Myanmar and Myanmar artemisinin resistance containment measures have been launched since 2009-2010.

* It is important to monitor the spread and magnitude of artemisinin resistant malaria in Myanmar.

* So, day-3 surveillance study have been conducted.

* Recently artemisinin resistant molecular marker, K13 have been identified and it was used as a tool in this study.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-07
• Primary Completion: 2013-12
• Study Completion: 2014-06
• Status Verified: 2014-07
• Study First Submitted: 2014-07-22
• Study First Submitted QC: 2014-07-22
• Last Update Submitted: 2014-07-22
• Study First Posted: 2014-07-23
• Last Update Posted: 2014-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 91

Inclusion Criteria

• confirmed uncomplicated falciparum malaria patients.
• age >2 years
• box sex
• given informed consent

Exclusion Criteria

• severe malaria
• did not give informed consent
• others diseases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
day-3 parasite positivity	3 days	All of the enrolled patients were monitored with appropriate care up to third day and take the samples on day-3.

Secondary Outcome Measures

Name	Time	Method
Prevalence of the drug resistance marker	up to day-3	By using the dried blood spots, drug resistance markers were detected by molecular method.

Trial Locations

Locations (1)

Dr. Myat Phone Kyaw; 🇲🇲 Yangon, Myanmar